Home » Stocks » Northwest Biotherapeutics

Northwest Biotherapeutics, Inc. (NWBO)

Stock Price: $0.353 USD 0.013 (3.68%)
Updated Aug 7, 2020 4:00 PM EDT - End of day

Stock Price Chart

Key Info

Market Cap 252.97M
Revenue (ttm) 2.64M
Net Income (ttm) 3.38M
Shares Out 710.28M
EPS (ttm) 0.01
PE Ratio 35.25
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 7, 2020
Last Price $0.353
Previous Close $0.340
Change ($) 0.013
Change (%) 3.68%
Day's Open 0.347
Day's Range 0.334 - 0.368
Day's Volume 1,469,634
52-Week Range 0.140 - 0.419

More Stats

Market Cap 252.97M
Enterprise Value 269.42M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 710.28M
Float 679.41M
EPS (basic) n/a
EPS (diluted) 0.01
FCF / Share -0.05
Dividend n/a
Dividend Yield n/a
Earnings Yield 2.84%
FCF Yield n/a
Payout Ratio n/a
Shares Short 14.14M
Short Ratio 13.54
Short % of Float 15.09%
Beta 1.62
PE Ratio 35.25
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 95.79
PB Ratio n/a
Revenue 2.64M
Operating Income -27.43M
Net Income 3.38M
Free Cash Flow -29.91M
Net Cash -16.45M
Net Cash / Share -0.02
Gross Margin -423.32%
Operating Margin -1,038.62%
Profit Margin 127.80%
FCF Margin -1,132.34%
ROA -101.89%
ROE n/a
ROIC -30.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$15.10*
Low
15.1
Current: $0.353
High
15.1
Target: 15.10
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue2.410.410.340.621.741.450.810.770.010.01
Revenue Growth484.95%22.62%-46.07%-64.17%19.6%79.73%4.79%7620%0%-
Gross Profit2.410.410.340.621.741.450.810.770.010.01
Operating Income-27.46-41.48-54.68-79.27-126-101-55.47-43.83-26.79-15.35
Net Income-20.30-35.79-73.14-80.21-115-136-65.79-67.32-32.83-27.37
Shares Outstanding56444024311177.7159.2532.8711.765.894.19
Earnings Per Share-0.04-0.12-0.31-0.77-1.48-2.29-2.00-5.72-5.58-6.56
Operating Cash Flow-31.86-34.59-36.50-55.65-79.71-54.58-37.80-22.75-14.71-6.38
Capital Expenditures-0.3645.400.21-4.94-6.75-33.73--0.03-0.05-0.04
Free Cash Flow-32.2210.82-36.28-60.59-86.46-88.30-37.80-22.79-14.76-6.42
Cash & Equivalents0.3722.220.126.8722.7014.2618.507.350.020.15
Total Debt18.0316.8031.4331.7122.8123.681.223.8715.269.95
Net Cash / Debt-17.665.43-31.31-24.84-0.11-9.4217.283.47-15.23-9.80
Assets9.1324.6748.9152.9170.8056.4618.787.570.210.29
Liabilities52.7071.8396.2079.4175.4791.4819.6912.6352.3927.98
Book Value-43.57-47.16-67.33-26.50-4.68-35.03-9.82-16.07-52.17-27.68
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Northwest Biotherapeutics, Inc.
Country United States
Employees 17
CEO Linda F. Powers

Stock Information

Ticker Symbol NWBO
Stock Exchange US OTC
Sector Healthcare
Industry Biotechnology
Unique Identifier OTCMKTS: NWBO

Description

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. It is developing DCVax-L, a product in Phase III clinical trials to treat Glioblastome multiforme, a brain cancer; and DCVax-Direct, a product in Phase I/II clinical trials to treat various types of inoperable solid tumor cancers. The company was founded in 1996 and is headquartered in Bethesda, Maryland.